Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Novo Nordisk lost its title of Europe’s biggest company by market capitalization to the luxury-goods maker LVMH.

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...